Introduction {#S0001}
============

Coronary artery disease (CAD) and acute myocardial infarction (MI) are a major cause of death and morbidity worldwide. Atherosclerosis is the major cause of cardiovascular disease (CVD) \[[@CIT0001], [@CIT0002]\]. Coronary atherosclerosis is the main cause of ST elevation acute myocardial infarction (STEMI). Multiple pathophysiological factors influence this atherosclerotic process, and one of the most important factors is inflammation \[[@CIT0003], [@CIT0004]\]. The inflammatory process that underlines atherosclerosis has a critical role in plaque destabilization. This process also affects the development of thrombus that is superimposed on the erosion of an atherosclerotic plaque and consequently causes MI \[[@CIT0005]\]. Reperfusion therapy, either pharmacological or mechanical, is indicated in patients with STEMI with duration of less than 12 h. The superiority of primary percutaneous coronary intervention (PPCI) over fibrinolysis has been demonstrated in several studies \[[@CIT0006], [@CIT0007]\]. However, it has been observed that the benefit of PPCI is different in each group of patients and the benefit is greatest in those at high risk \[[@CIT0008]\]. Thus, risk stratification prior to intervention has great clinical importance to identify patients at higher risk and to optimize their therapeutic management. The risk scores applied to patients who are treated exclusively with PPCI have shown favorable results \[[@CIT0009], [@CIT0010]\]. The thrombolysis in myocardial infarction (TIMI) risk score for STEMI was calculated as the sum of independent predictors of mortality and ischemic events \[[@CIT0011]\] and derived from STEMI patients in the In TIME II randomized controlled trial \[[@CIT0012]\].

Several studies have shown that the neutrophil to lymphocyte ratio (NLR) is a prognostic marker in patients with CAD \[[@CIT0013], [@CIT0014]\]. Platelets are a source of inflammatory mediators \[[@CIT0015]\]. However, platelets have a major effect on the formation of atherothrombosis, and therefore play an important role in the pathogenesis of acute coronary syndrome (ACS) \[[@CIT0016]\]. The association between low lymphocyte count and major adverse cardiovascular outcomes (MACE) has also been shown in several studies \[[@CIT0017], [@CIT0018]\]. Recently, the platelet to lymphocyte ratio (PLR) has been proposed to be a pro-thrombotic and inflammatory marker \[[@CIT0018]--[@CIT0020]\]. The relationship between NLR, PLR and TIMI risk score in patients with STEMI has never been studied.

Aim {#S0002}
===

In this study, we investigated the association between TIMI risk score and NLR, PLR and other biochemical indices in patients with STEMI undergoing PPCI.

Material and methods {#S0003}
====================

Study design and patients {#S20004}
-------------------------

We evaluated 750 patients who retrospectively presented with STEMI and underwent PPCI within 12 h of symptom onset between January 2012 and January 2014. We defined STEMI based on criteria created by the American College of Cardiology and the European Society of Cardiology \[[@CIT0021]\] as: an increase in troponin I \> 1 ng/ml; a new ST elevation as measured from the J-point in 2 or more contiguous leads from leads V1, V2, and V3 measuring at least 0.2 mV or at least 0.1 mV in the remaining leads during the first 12 h after symptom onset or newly developed left bundle branch block (LBBB) pattern.

Patients with severe liver disease, autoimmune diseases, cancer, hematological disorders, severe valvular disease, inflammatory, and infectious diseases were excluded from the study. Patients on the following medications were excluded from the study: thrombolytic therapy and glycoprotein IIb/IIIa inhibitors. If at any point during the study the patient was not treated with PPCI, did not follow up for blood work, or had poor echocardiographic windows, they were also eliminated from the investigation. After accounting for all of these exclusion criteria, a total of 390 patients remained in the study sample. All patients received a complete physical examination and assessment of coronary risk factors. We recorded medical histories and presenting clinical symptoms. Patients were also evaluated according to Killip clinical examination classification \[[@CIT0022]\].

Demographic data and variables determined TIMI risk score points. A total score of 0-14 was possible according to the following characteristics: age, diabetes mellitus (DM)/hypertension (HT) or angina, heart rate \< 100 bpm, systolic blood pressure \< 100 mmHg, Killip class II--IV, weight \< 67 kg, anterior MI or LBBB presentation, latency \> 4 h \[[@CIT0011]\]. Calculation of the TIMI risk score was performed with a computer program (<http://www.mdcalc.com/timi-risk-score-for-stemi/>). Patients were classified as low risk if their TIMI score was ≤ 4 points (group I) and as high risk if their TIMI score was \> 4 points (group II). The in-hospital death Global Registry of Acute Coronary Events (GRACE) risk score points (which include age, creatinine, heart rate, systolic blood pressure, Killip class, cardiac arrest at admission, elevated cardiac markers, and ST-segment deviation) were recorded \[[@CIT0023]\], and calculation of the GRACE risk score was performed using a computer program ([www.outcomesumassmed.org/grace/acs_risk/acs_risk_content.html](http://www.outcomesumassmed.org/grace/acs_risk/acs_risk_content.html)).

Monitoring for MACE was performed during the in-hospital follow-up period. Examples of MACE were acute stent thrombosis, cardiogenic shock, new advanced heart failure, pulmonary edema, complete atrioventricular block (AVB) requiring a temporary pacemaker, severe ventricular arrhythmia and in-hospital mortality during the post-PPCI follow-up period. An in-hospital death was only considered a MACE if the death was due to myocardial infarction, cardiac arrest, or some other cardiac-related cause.

Acute stent thrombosis was defined as an abrupt onset of cardiac symptoms after stent deployment within the first 24 h with evidence of a flow-limiting thrombus on angiography near the newly placed stent. Cardiogenic shock was defined as marked and persistent hypotension lasting more than 30 min with a systolic arterial pressure less than 80 mm Hg with signs of hypoperfusion due to left ventricular dysfunction, right ventricular infarction, or cardiac mechanical complications. New-onset advanced heart failure was diagnosed if the patient qualified for a New York Heart Association functional classification of III or greater. In order for a severe ventricular arrhythmia to be considered a MACE, it needed to occur within 48 h of admission, and the rhythm had to be ventricular fibrillation, ventricular tachycardia, or asystole.

Transthoracic echocardiography was performed upon admission to determine left ventricular ejection fraction (LVEF) (Vivid S6, GE Medical Systems, USA). All patients underwent selective coronary angiography using the Judkins technique. We performed PPCI with the standard femoral approach using a 7 Fr guiding catheter. For all study participants, only one artery was identified as the culprit lesion. Coronary vessel disease was defined as greater than a 50% stenosis in one of the major coronary arteries. The Gensini scoring system was used to determine the severity of CAD \[[@CIT0024]\].

Laboratory analysis {#S20005}
-------------------

On admission, we obtained venous blood from all patients. The NLR was calculated as the ratio of the neutrophils and lymphocytes, both obtained from the same automated blood sample at admission. Baseline PLR was measured by dividing the platelet count by the lymphocyte count. Hematologic indices were measured by an automated hematology analyzer system (Abbott Cell-Dyn 3700; Abbott Laboratory, Abbott Park, Illinois). Absolute cell counts were utilized to perform subsequent analyses. Total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, glucose, uric acid level (UA) and creatinine levels were measured with the Abbott Architect C16000 autoanalyzer (Abbott Laboratory). Fasting lipid panels were obtained after an overnight fast.

Statistical analysis {#S20006}
--------------------

Statistical analyses were performed using the SPSS software version 18.0 (SPSS Inc., Chicago, Illinois, USA). Categorical variables were summarized as percentages and compared with the Pearson χ^2^ test. Continuous variables were presented as mean ± standard deviation and tested for normal distribution by the Kolmogorov-Smirnov test. Comparative analyses between groups were performed using the χ^2^ or Fisher\'s exact test and independent samples *t*-test or Mann-Whitney *U*-test, when appropriate. Spearman\'s test was used for correlation analysis between TIMI risk score for STEMI and other parameters. Multivariate stepwise forward logistic regression analysis was used to assess independent predictors of TIMI risk score for STEMI. All variables that were found to be significant in univariate analysis were included in the logistic regression model, and results are shown as an odds ratio (OR) with 95% confidence intervals (CI). A *p*-value less than 0.05 was considered significant. The cut-off points for sensitivity and specificity of TIMI risk score for STEMI in predicting in-hospital mortality were estimated by performing a receiver operator characteristic (ROC) curve analysis.

The study protocol was reviewed and approved by the Ethics Committee in accordance with the Declaration of Helsinki.

Results {#S0007}
=======

We obtained data from a total of 756 patients with STEMI, who were taken to the catheterization laboratory to undergo PPCI. After accounting for exclusion criteria, 390 patients were included in the data analysis. The distribution of patients according to TIMI score was as follows: 1 point, 49 patients (12.6%); 2 points, 74 patients (19.0%); 3 points, 51 patients (13.1%); 4 points, 78 patients (20.0%); 5 points, 44 patients (11.3%); 6 points, 30 patients (7.7%); 7 points, 31 patients (7.9%); and ≥ 8 points, 33 patients (8.4%). The study population was divided into two groups according to TIMI risk scores as: group I (≤ 4, *n* = 252) and group II (\> 4, *n* = 138). Mean TIMI risk scores for groups I and II were 2.6 and 6.8, respectively. Comparisons of the baseline characteristics of the groups are shown in [Table I](#T0001){ref-type="table"}.

###### 

Demographic characteristics of patients according to TIMI-STEMI risk score groups

  Variables                                TIMI ≤ 4 points *n* = 252   TIMI \> 4 points *n* = 138   Value of *p*
  ---------------------------------------- --------------------------- ---------------------------- ----------------------------------------------
  Age \[years\]                            56.85 ±11.73                71.20 ±11.83                 \< 0.001[\*\*](#TF0002){ref-type="table-fn"}
  Sex, male, *n* (%)                       201 (80)                    82 (59)                      \< 0.001
  Previous history:                                                                                 
   Hypertension, *n* (%)                   86 (34)                     55 (40)                      0.260
   Diabetes mellitus, *n* (%)              63 (25)                     36 (26)                      0.814
   Smoking, *n* (%)                        159 (63)                    58 (42)                      \< 0.001
   Hyperlipidemia, *n* (%)                 13 (5)                      7 (5)                        0.971
   Family history of CAD, *n* (%)          63 (25)                     15 (11)                      0.001
   MI or CAD, *n* (%)                      12 (5)                      8 (6)                        0.658
   PCI, *n* (%)                            15 (6)                      7 (5)                        0.719
  Previous medications:                                                                             
   Preadmission aspirin use, *n* (%)       192 (76)                    104 (75)                     0.855
   Preadmission clopidogrel use, *n* (%)   126 (50)                    65 (47)                      0.584
   β-Blocker, *n* (%)                      29 (12)                     12 (9)                       0.399
   ACE inhibitors, *n* (%)                 28 (11)                     13 (9)                       0.603
   Statin, *n* (%)                         16 (6)                      13 (9)                       0.269
   Preadmission enoxaparin use, *n* (%)    231 (92)                    118 (35)                     0.058
  Killip class on presentation, *n* (%):                                                            
   I                                       234 (93)                    60 (44)                      \< 0.001
   II                                      16 (6.2)                    47 (34)                      
   III                                     1 (0.4)                     14 (10)                      
   IV                                      1 (0.4)                     17 (12)                      
  Admission SBP \[mm Hg\]                  129.13 ±21.09               123.82 ±29.30                0.062[\*](#TF0001){ref-type="table-fn"}
  Admission heart rate \[bpm\]             80.52 ±14.99                88.37 ±19.52                 \< 0.001[\*](#TF0001){ref-type="table-fn"}
  Location of STEMI:                                                                                
   Anterior, *n* (%)                       92 (37)                     88 (64)                      \< 0.001
   Non-anterior, *n* (%)                   160 (63)                    50 (36)                      
   Latency \[h\]                           5.08 ±3.21                  7.18 ±3.50                   \< 0.001[\*\*](#TF0002){ref-type="table-fn"}
   Admission LVEF (%)                      46.22 ±9.36                 37.96 ±10.62                 \< 0.001[\*\*](#TF0002){ref-type="table-fn"}
  Location of culprit lesion:                                                                       
   LAD, *n* (%)                            97 (39)                     88 (64)                      \< 0.001
   RCA, *n* (%)                            117 (46)                    30 (22)                      
   CX, *n* (%)                             38 (15)                     19 (14)                      
  Number of narrowed coronary arteries:                                                             
   1 vessel, *n* (%)                       117 (46)                    47 (34)                      0.018
   \> 1 vessel, *n* (%)                    135 (54)                    91 (66)                      
  Gensini score                            56.07 ±28.32                68.10 ±34.59                 0.001[\*\*](#TF0002){ref-type="table-fn"}
  GRACE risk score                         138.75 ±27.59               192.49 ±41.69                \< 0.001[\*\*](#TF0002){ref-type="table-fn"}
  Duration of hospitalization \[days\]     5.03 ±4.5                   6.54 ±7.29                   0.001[\*\*](#TF0002){ref-type="table-fn"}

Student\'s t-test,

Mann-Whitney U-test, For other statistics χ^2^ test, MI -- myocardial infarction, CAD -- coronary artery disease, PCI -- percutaneous coronary intervention, ACE -- angiotensin converting enzyme, SBP -- systolic blood pressure, LVEF -- left ventricular ejection fraction, LAD -- left anterior descending coronary artery, RCA -- right coronary artery, CX -- circumflex coronary artery, TIMI -- thrombolysis in myocardial infarction, GRACE -- Global Registry of Acute Coronary Events.

The average age of the population was 61.93 ±13.62 years and 72.6% were men. In comparison to group I, patients in group II were older. There were no significant differences regarding known atherogenic risk factors and previous medications, but smoking was greater in group I (*p* \< 0.001). Killip class II-IV designations were more common in group II (*p* \< 0.001). The majority of group II patients had an anterior MI caused by an occlusion of the left anterior descending coronary artery (LAD). Moreover, patients in group II showed higher rates of multivessel disease (*p* = 0.018). Patients in group II had lower LVEF measurements than group I (*p* \< 0.001). Duration of hospitalization was significantly longer in group II patients (*p* = 0.001). The Gensini and GRACE scores were higher in group II when compared to group I (*p =* 0.001, *p* \< 0.001). Initial laboratory findings are shown in [Table II](#T0002){ref-type="table"}.

###### 

Biochemical findings of patients according to TIMI-STEMI risk score groups

  Variables                             TIMI ≤ 4 points   TIMI \> 4 points   Value of *p*
  ------------------------------------- ----------------- ------------------ --------------------------------------------
  White blood cell count \[K/µl\]       13.25 ±4.60       14.18 ±6.57        0.147
  Neutrophil count                      10.48 ±4.35       11.39 ±6.05        0.122
  Lymphocyte count                      2.03 ±1.24        1.89 ±1.18         0.272
  Neutrophil to lymphocyte ratio        6.70 ±4.17        8.36 ±7.07         0.016
  Platelet count \[K/µl\]               251.43 ±62.36     249.09 ±70.32      0.461
  Platelet to lymphocyte ratio          157.63 ±84.71     180.06 ±133.04     0.087
  Mean platelet volume                  8.16 ±1.49        8.39 ±1.44         0.144
  Red cell distribution width           15.89 ±1.53       16.18 ±1.51        0.08
  Platelet distribution width           17.76 ±1.08       18.13 ±1.34        0.008
  Monocyte count                        0.65 ±0.30        0.70 ±0.35         0.205
  Basophil count                        0.07 ±0.05        0.07 ±0.06         0.539
  Red blood cell count \[M/µl\]         4.95 ±0.57        4.73 ±0.58         \< 0.001[\*](#TF0003){ref-type="table-fn"}
  Hemoglobin \[g/dl\]                   14.02 ±1.65       13.49 ±1.65        0.002[\*](#TF0003){ref-type="table-fn"}
  Glucose on admission \[mg/dl\]        170.26 ±89.06     192.89 ±100.77     0.013[\*](#TF0003){ref-type="table-fn"}
  Creatinine on admission \[mg/dl\]     0.93 ±0.77        1.04 ±0.53         0.001[\*](#TF0003){ref-type="table-fn"}
  Uric acid \[mg/dl\]                   6.72 ±2.57        7.24 ±2.60         0.030[\*](#TF0003){ref-type="table-fn"}
  Fasting lipid panel:                                                       
   Total cholesterol \[mg/dl\]          178.99 ±41.32     184.30 ±48.99      0.260
   Low-density lipoprotein \[mg/dl\]    114.30 ±34.27     119.62 ±33.15      0.142
   High-density lipoprotein \[mg/dl\]   34.68 ±8.63       36.14 ±11.11       0.186
   Triglycerides \[mg/dl\]              158.33 ±91.16     140.88 ±95.88      0.078

Mann-Whitney U-test; For other statistics Student\'s t-test.

In comparison to group I, glucose on admission (*p* = 0.013), creatinine on admission (*p* = 0.001), UA (*p* = 0.030), NLR (*p* = 0.016) and PDW (*p* = 0.008) values ([Figure 1](#F0001){ref-type="fig"}) for patients in group II were significantly greater than those of group I. The was no significant difference between groups for PLR and fasting lipid panels.

![**A** -- Box plot presentation comparison of NLR and TIMI risk score groups. **B** -- Box plot presentation comparison of PDW and TIMI risk score groups. **C** -- Box plot presentation comparison of uric acid level and TIMI risk score groups](PWKI-11-25285-g001){#F0001}

Adverse events that occurred in both groups during hospitalization are shown in [Table III](#T0003){ref-type="table"}. We observed that in-hospital mortality (*p* \< 0.001) and MACE (*p* \< 0.001) were significantly higher in patients of group II. Similarly, other adverse events also occurred more frequently in group II. In-hospital advanced heart failure (*p* \< 0.001), advanced pulmonary edema (*p* \< 0.001), development cardiogenic shock (*p* \< 0.001) and serious ventricular arrhythmias (*p* \< 0.001) were more common in group II patients.

###### 

Major adverse cardiovascular events according to TIMI-STEMI risk score groups

  Variables                                             TIMI ≤ 4 points   TIM \> 4 points   Value of *p*
  ----------------------------------------------------- ----------------- ----------------- -----------------------------------------
  In-hospital MACE, *n* (%)                             36 (14)           59 (43)           \< 0.001
  Advanced heart failure, *n* (%)                       6 (2)             20 (15)           \< 0.001
  Advanced pulmonary edema, *n* (%)                     4 (2)             15 (11)           \< 0.001
  Cardiogenic shock, *n* (%)                            7 (3)             26 (19)           \< 0.001
  Acute stent thrombosis, *n* (%)                       8 (3)             3 (2)             0.753[\*](#TF0004){ref-type="table-fn"}
  Complete AVB requiring transient pacemaker, *n* (%)   11 (4)            11 (8)            0.140
  Serious ventricular arrhythmia, *n* (%)               10 (4)            23 (17)           \< 0.001
  In-hospital mortality, *n* (%)                        11 (4)            33 (24)           \< 0.001

Fisher\'s exact test; For other statistics χ^2^ test; MACE -- major adverse cardiovascular event, AVB -- atrioventricular block.

Spearman\'s correlation analysis revealed significant associations between age (*r* = 0.626, *p* \< 0.001), heart rate (*r* = 0.271, *p* \< 0.001), latency (*r* = 0.313, *p* ≤ 0.001), creatinine on admission (*r* = 0.244, *p* \< 0.001), glucose on admission (*r* = 0.169, *p* \< 0.001), LVEF (*r* = --0.440, *p* \< 0.001), GRACE risk score (*r* = 0.736, *p* \< 0.001), Killip class (*r* = 0.271, *p* \< 0.001), NLR (*r* = 0.113, *p* = 0.032), PDW (*r* = 0.110, *p* = 0.029) and TIMI score.

Stepwise forward multivariable logistic regression analysis was used to assess the independent association of clinical parameters with high TIMI risk score. Older age (*b* = 0.057, odds ratio (OR) 1.059, 95% CI: 1.023--1.095, *p* = 0.001), increased heart rate (*b* = 0.028, OR = 1.028, 95% CI: 1.006--1.051, *p* = 0.012) latency (*b* = 0.214, OR = 1.239, 95% CI: 1.118--1.373, *p* \< 0.001), LVEF on admission (*b* = --0.060, OR = 0.942, 95% CI: 0.911--0.974, *p* \< 0.001), creatinine on admission (*b* = --0.745, OR = 0.475, 95% CI: 0.247--0.912, *p* = 0.025), and higher GRACE risk score (*b* = 0.049, OR = 1.050, 95% CI: 1.033--1.068, *p* \< 0.001) were independently associated with a higher TIMI risk score for STEMI.

In ROC analysis, a cut-off point of \> 4 TIMI score predicted in-hospital mortality (sensitivity 75.0%, specificity 69.7%, and area under curve (AUC) 0.782, 95% CI: 0.705--0.859; *p* \< 0.001) ([Figure 2](#F0002){ref-type="fig"}).

![Receiver operator characteristic curve analysis of high TIMI risk score in predicting in-hospital mortality](PWKI-11-25285-g002){#F0002}

Discussion {#S0008}
==========

We showed that hematologic indices such as NLR, PDW and UA level were significantly associated with TIMI risk score for STEMI patients. Also, we demonstrated that admission LVEF, duration of chest pain, duration of hospitalization, Gensini and GRACE risk scores were significantly associated with TIMI risk score. Moreover, TIMI risk score and NLR, PDW and admission LVEF are significantly correlated. We found that there was a positive correlation of NLR and negative correlation of LVEF with TIMI risk score. Furthermore, LVEF was independently associated with TIMI risk score for STEMI. However, TIMI score was significantly associated with in-hospital MACE and in-hospital mortality in STEMI patients undergoing PPCI. Moreover, a TIMI score of greater than 4 was the cut-off point for predicting higher in-hospital mortality with a sensitivity of 75% and a specificity of 70%.

Effective risk stratification is integral to the management of patients with ACS \[[@CIT0025]\]. Even among patients with STEMI, for whom initial therapeutic options are well defined, patient risk characteristics have an effect on early therapeutic decision making \[[@CIT0006], [@CIT0026], [@CIT0027]\]. In addition, increasing economic pressures have intensified the need for appropriate triage and clinical resource utilization, including decisions regarding transfer to tertiary centers \[[@CIT0028]\]. In particular, the capacity to reliably identify patients at very low risk for fatal recurrent events may offer the opportunity to select low-risk patients for early hospital discharge \[[@CIT0029], [@CIT0030]\]. Consequently, tools that enhance the clinician\'s ability to rapidly and accurately assess risk are of substantial interest. There are few models that have integrated weighing information from multivariate regression in a fashion similar to the TIMI risk score. Currently, there are no models which predict the short-term outcomes in STEMI \[[@CIT0031]\].

A potentially relevant issue in the treatment of patients with STEMI is that this population is highly heterogeneous regarding their risk of adverse events. Thus, their correct stratification becomes essential in evaluating their prognosis and making accurate therapeutic decisions. An ideal risk score must be useful, simple and fast in order to predict short- and long-term prognosis \[[@CIT0032], [@CIT0033]\]. The TIMI risk score for STEMI is a clinical stratification calculated with data obtained at hospital presentation that can easily classify low and high risk patients. This risk score revealed that about 20% of patients were at higher risk of death \[[@CIT0034]\]. The analysis was subsequently validated in an unselected patient population in the National Registry of Myocardial Infarction \[[@CIT0007]\] and showed a strong predictive value for mortality in patients treated with thrombolytic therapy \[[@CIT0035]\].

The TIMI risk score for STEMI serves as a prognostic calculator that discriminates high-risk patients with the combination of baseline variables that are part of the routine medical evaluation \[[@CIT0011]\]. The TIMI risk score for STEMI has a strong association with mortality at 30 days. Patients with a score \> 8 points had a 40-fold increase in mortality. At the high end, a score \> 5 points identified 12% of patients with a mortality risk \> 2-fold higher than the mean for the population. In contrast, the 12% of patients with a risk score of 0 had a mortality rate \< 1% \[[@CIT0011]\]. The TIMI risk score for STEMI is used for objective risk stratification of patients into one of two groups: low (≤ 4 points); and high (\> 4 points). The increased score is associated with higher in-hospital mortality and adverse cardiovascular events \[[@CIT0036]\]. Thus, in our study we categorized the patients as having either a low (≤ 4 points) or a high (\> 4 points) score.

In our study of 390 patients who underwent PPCI, 35% (*n* = 138) were stratified as having a high risk score before the procedure. Thune *et al*. in the DANish trial in Acute Myocardial Infarction-2 (DANAMI-2) stratified patients by TIMI risk score; 25% of patients were high risk (TIMI score \> 4 points) \[[@CIT0037]\]. Lev *et al*., without identifying a high-risk group, reported that stratification with the TIMI risk score in patients undergoing PPCI predicts mortality and MACE (death, myocardial infarction, target vessel revascularization) \[[@CIT0038]\].

We applied the TIMI risk score for STEMI in a group of patients who underwent PPCI and found that an increase in TIMI risk score is associated with increased frequency of in-hospital death. The TIMI risk score was developed to predict mortality. An important clinical implication of this study is that it identified a group of high-risk patients, who not only have a mortality rate higher than the low-risk group, but also have an increased frequency of in-hospital adverse events such as heart failure, development of cardiogenic shock, ventricular arrhythmias and advanced pulmonary edema.

The TIMI risk score for STEMI has been validated prospectively in various studies. The TIMI risk score for STEMI reliably identifies patients at very high risk while maintaining good discriminatory capacity in the low-risk range, where smaller absolute differences are more likely to impact clinical decisions. The TIMI risk scores include variables such as age, DM/HT or angina, heart rate \< 100 bpm, systolic blood pressure \< 100 mm Hg, Killip class II--IV, weight \< 67 kg, anterior MI or LBBB presentation, and latency \> 4 h, but do not include inflammatory markers.

NLR and TIMI risk score for STEMI {#S20009}
---------------------------------

Several studies have examined the role of neutrophils and lymphocytes in modulating the inflammatory response to myocardial injury \[[@CIT0039], [@CIT0040]\]. The NLR is a novel prognostic inflammatory marker \[[@CIT0013], [@CIT0014]\]. Recently several studies have demonstrated that NLR is a marker of CVD prognosis \[[@CIT0014], [@CIT0041], [@CIT0042]\]. Arbel *et al*. found that increased NLR was associated with increased severity of CAD, thereby providing additive predictive value to conventional risk factors and commonly used biomarkers e.g. C-reactive protein (CRP) and total WBC count \[[@CIT0043]\].

Polat *et al*. reported that increased NLR was significantly associated with increased severity of rheumatic mitral valvular disease \[[@CIT0044]\]. Yildiz *et al*. reported that increased NLR was independently and significantly associated with ventricular premature contraction existence \[[@CIT0045]\].

We tested the predictive value of NLR with a well-validated standardized MI risk score. We have shown that NLR is significantly associated with TIMI-STEMI risk score. Multiple ACS studies now support the use of NLR as an admission biomarker, which can be used to determine prognosis \[[@CIT0046], [@CIT0047]\]. The NLR can be readily calculated at point of care, thereby facilitating short- and long-term risk prediction for STEMI patients, even prior to revascularization. To our knowledge, the relationship between the NLR and TIMI risk score for STEMI has not been investigated. Our results demonstrate for the first time the predictive value of the TIMI risk score, STEMI and NLR. We found that high NLR was significantly positively correlated with TIMI risk score for STEMI.

PLR and TIMI risk score for STEMI {#S20010}
---------------------------------

Platelets play an important role in the pathogenesis of ACS \[[@CIT0016]\], which is caused by complex interactions between leukocytes and platelets. This results in the production of reactive oxygen species contributing to ischemic endothelial damage \[[@CIT0048]\]. Prior studies have demonstrated that a low lymphocyte count in patients with acute MI and chronic CAD gives information about worse prognosis \[[@CIT0049]\]. Platelet to lymphocyte ratio is derived from the number of platelets and lymphocytes. The prognostic significance of the PLR has been demonstrated in patients with some cancers \[[@CIT0019], [@CIT0020]\]. It has been proposed to be a pro-thrombotic and inflammatory marker \[[@CIT0050], [@CIT0051]\]. Azab *et al*. reported that higher PLR values were associated with increased long-term mortality in non-STEMI patients \[[@CIT0050]\]. Yildiz *et al*. found that high preprocedural PLR and NLR levels were significant and independent predictors of no reflow in patients undergoing PPCI \[[@CIT0052]\]. Sunbul *et al*. determined that the PLR was a significant predictor of being a "non-dipper" or a hypertensive patient who sustains high blood pressures throughout the night time \[[@CIT0053]\]. However, to the best of our knowledge, the relationship between the PLR and TIMI risk score for STEMI has not been investigated before. We found that high PLR was not significantly correlated with TIMI risk score for STEMI.

PDW and TIMI risk score for STEMI {#S20011}
---------------------------------

Platelet distribution width (PDW) is a direct measurement of the variability in platelet size and is a marker of platelet activation \[[@CIT0054]\]. In a recently conducted study, along with the demonstration of a relationship between CAD and PDW, there was also a significant relationship found between PDW and saphenous vein graft patency in patients who had coronary artery bypass operations \[[@CIT0055]\]. Vagdatli *et al*. \[[@CIT0056]\] reported that PDW is a more specific indicator of platelet activation than mean platelet volume (MPV), since there was no platelet swelling. The PDW directly measures the variability in platelet size and is a marker of platelet activation \[[@CIT0057]\]. In a study with diabetic patients, Jindal *et al*. found a significant relationship between increased PDW and microvascular dysfunction \[[@CIT0058]\]. Khandekar *et al*. found that PDW was significantly higher in patients with acute MI and unstable angina pectoris \[[@CIT0059]\]. We found that high PDW was significantly correlated with an increased TIMI risk score for STEMI. To our knowledge, the relationship between the PDW and TIMI risk score for STEMI has not been investigated before. Our results demonstrate the relationship between TIMI risk score for STEMI and PDW.

Uric acid and TIMI risk score for STEMI {#S20012}
---------------------------------------

Uric acid levels are closely associated with inflammatory markers such as CRP \[[@CIT0060]\]. Previous studies have shown that there was a significant relationship between UA levels and CAD \[[@CIT0061]--[@CIT0063]\], endothelial dysfunction \[[@CIT0064]\], coronary reserve \[[@CIT0065]\], coronary blood flow in patients undergoing elective angiography \[[@CIT0066]\] and in STEMI patients undergoing PPCI \[[@CIT0067]\]. Bickel *et al*. \[[@CIT0061]\] demonstrated that UA is an independent predictor of mortality in patients with CAD. Bos *et al*. \[[@CIT0062]\] reported that elevated UA levels are associated with an increased risk for acute MI. Recently UA levels were correlated with increased in-hospital MACE \[[@CIT0067]\]. Lazzeri *et al*. \[[@CIT0063]\] reported that UA is a prognostic indicator of in-hospital mortality in acute STEMI patients. In our study, we found that elevated UA levels were significantly associated with TIMI risk score for STEMI. To our knowledge, only one study by Wildi *et al*. has investigated the relationship between UA level and TIMI risk score for suspected MI \[[@CIT0068]\]. Specifically, they investigated the relationship between UA levels and TIMI risk score in 143 patients (26% STEMI, 75% non-STEMI). They found that UA values at presentation were associated with cardiovascular risk factors.

In our study, we found that NLR and UA, which are markers of inflammation, and PDW, which is a marker of platelet activation, are significantly associated with TIMI risk score in the STEMI patients before PPCI, but PLR is not significantly associated with TIMI risk score. We suggest that NLR, PDW and UA biomarkers, which are easily and cheaply measured, may be used in risk stratifying STEMI patients before PPCI. To our knowledge, this is the first study to report the joint relationship between UA level, PLR, NLR and PDW with TIMI risk score for STEMI before PPCI. Our data included biochemical blood samples analyzed at admission, before starting any medication. We analyzed these blood samples prior to starting medication because WBC, its subtypes and platelets could be affected by infectious disorders, anxiety, and medication. Time of admission is the most critical time for clinicians to determine the choice of reperfusion therapy based on the predicted interventional outcome of the presenting case. Pre-admission or initial presentation prognostic indices are of vital importance in the accurate triage of emergency room patients for STEMI revascularization.

The limitations of the present study were a retrospective design and single-center experience. We could not compare NLR, PLR with other inflammatory markers, such as CRP, fibrinogen, or myeloperoxidase, because they were not routinely obtained in our study population.

Conclusions {#S0013}
===========

Neutrophil to lymphocyte ratio, PDW and UA level are convenient, inexpensive and reproducible biomarkers for STEMI prognosis before PPCI. They can be utilized as robust stand-alone prognostic indicators for patients presenting with STEMI, even before accounting for eventual angiographic findings and outcomes. When these indicators are combined with standardized clinical mortality risk prediction scores, they markedly augment the predictive power of TIMI risk score. The interaction of the TIMI-STEMI risk score with these prognostic measures may be an area of interest for future investigation. We believe that these significant findings of our analysis can guide further clinical practice.
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